Filtros de búsqueda

Lista de obras de

2016 ESC GUIDELINES FOR THE MANAGEMENT OF ATRIAL FIBRILLATION DEVELOPEDIN COLLABORATION WITH EACTS

artículo científico publicado en 2017

2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS

article by Paulus Kirchhof et al published January 2017 in Revista Española de Cardiología

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

article by Paulus Kirchhof et al published 27 August 2016 in EP Europace

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

artículo científico publicado en 2016

A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score

artículo científico publicado en 2017

A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference

artículo científico publicado en 2015

ABSTRACTS

scholarly article

Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease

artículo científico publicado en 1999

All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome

artículo científico publicado en 2016

An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease

artículo científico publicado en 2005

Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE-LY trial

artículo científico publicado en 2015

Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Are Associated With Improved Outcome but Do Not Prevent New-Onset Atrial Fibrillation After Acute Myocardial Infarction

artículo científico publicado en 2017

Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation

scientific article published on 27 September 2020

Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI

scientific article published on 01 December 2020

Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention

artículo científico publicado en 2017

Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial.

artículo científico publicado en 2018

Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial

artículo científico publicado en 2016

Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation

artículo científico publicado en 2016

Artificial neural network algorithms for early diagnosis of acute myocardial infarction and prediction of infarct size in chest pain patients

artículo científico publicado en 2006

Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction

artículo científico publicado en 2015

Atrial fibrillation in patients undergoing coronary artery surgery is associated with adverse outcome

artículo científico publicado en 2018

Author reply

artículo científico publicado en 2014

Authors' response: From monitoring to vigilance about patient adherence to new oral anticoagulants

article

BLEEDING EVENTS AND THEIR CONSEQUENCES ON CARDIOVASCULAR EVENTS, READMISSION AND NET CLINICAL BENEFIT

artículo científico publicado en 2018

Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation

artículo científico publicado en 2013

Biomarkers in atrial fibrillation: a clinical review

artículo científico

Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE - LY Trial

Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy

artículo científico publicado en 2012

Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis

scientific article published on 26 March 2020

Coagulation activity and clinical outcome in unstable coronary artery disease

artículo científico publicado en 2001

Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard?

artículo científico

Combining different biochemical markers of myocardial ischemia does not improve risk stratification in chest pain patients compared to troponin I alone

artículo científico publicado en 2005

Comparison of Dabigatran Plus a P2Y12 Inhibitor with Warfarin-Based Triple Therapy across Body Mass Index in RE-DUAL PCI

scientific article published on 07 May 2020

Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial

artículo científico publicado en 2017

Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial

artículo científico

Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After

scientific article published on 09 December 2019

Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation

artículo científico publicado en 2018

Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial

artículo científico publicado en 2012

Coronary angiography in out-of-hospital cardiac arrest without ST elevation on ECG-Short- and long-term survival

artículo científico publicado en 2018

D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy.

artículo científico publicado en 2016

DOES RENAL FUNCTION INFLUENCE THE BENEFIT OF DUAL ANTITHROMBOTIC THERAPY WITH DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION? RESULTS FROM RE-DUAL PCI

artículo científico publicado en 2018

Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation

artículo científico publicado en 2020

Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes

scientific article published on 01 December 2019

Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation Post-PCI: Time in Therapeutic Range

scientific article published on 01 November 2019

Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial

artículo científico publicado en 2020

Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial

scholarly article by Jonas Oldgren et al published 14 May 2019 in European Heart Journal

Dabigatran etexilate and reduction in serum apolipoprotein B

artículo científico publicado en 2015

Dabigatran versus warfarin in patients with atrial fibrillation

artículo científico publicado en 2009

Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion

artículo científico publicado en 2011

Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial

artículo científico publicado en 2011

Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fi

artículo científico publicado en 2016

Design of DISCO-Direct or Subacute Coronary Angiography in Out-of-Hospital Cardiac Arrest study

artículo científico publicado en 2017

Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction

artículo científico publicado en 2004

Direct or subacute coronary angiography in out-of-hospital cardiac arrest (DISCO)-An initial pilot-study of a randomized clinical trial

scientific article published on 24 April 2019

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation

artículo científico publicado en 2017

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation

artículo científico publicado en 2018

Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST elevation myocardial infarction: results from the randomised RE-DUAL PCI trial

artículo científico publicado en 2020

EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary.

artículo científico publicado en 2013

Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM Trial

artículo científico publicado en 2007

Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial

scientific article published on 07 April 2020

Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEE

artículo científico publicado en 2008

Effects of apixaban compared with warfarin as gain in event-free time - a novel assessment of the results of the ARISTOTLE trial

scientific article published on 07 November 2019

Effects of dabigatran according to age in atrial fibrillation

artículo científico publicado en 2017

Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment

artículo científico publicado en 2007

Effects of sauna bath on heart failure: A systematic review and meta-analysis

scientific article published on 21 November 2018

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

artículo científico publicado en 2010

Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis

artículo científico publicado en 2018

Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis

artículo científico

Efficacy and safety of dabigatran versus warfarin from the RE-LY trial

artículo científico publicado en 2018

European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation

artículo científico publicado en 2013

Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials

scientific article published on 01 September 2020

Genetic determinants of dabigatran plasma levels and their relation to bleeding

artículo científico publicado en 2013

Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy

artículo científico publicado en 2016

Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial

artículo científico publicado en 2017

Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS

Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study

scientific article published on 15 January 2020

IS IT SAFE TO SWITCH OAC IN PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION? RESULTS FROM A RE-DUAL PCI SUBANALYSIS

artículo científico publicado en 2018

Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy

artículo científico publicado en 2014

Incidence and outcome of myocardial infarction treated with percutaneous coronary intervention during COVID-19 pandemic

scientific article published on 06 October 2020

Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A COllaboration between Multiple inst

scientific article published on 06 December 2020

Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease

artículo científico publicado en 2005

Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference

artículo científico publicado en 2018

Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation

artículo científico publicado en 2015

Is the ESC blowing its own trumpet or should it have a deserved fanfare? The impact and power of registry data

artículo científico publicado en 2022

Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients

artículo científico publicado en 2007

Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation

artículo científico publicado en 2016

Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction

artículo científico publicado en 2005

Low Walking Impairment Questionnaire score after a recent myocardial infarction identifies patients with polyvascular disease

scholarly article published in JRSM cardiovascular disease

Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study

artículo científico publicado en 2017

Low-dose acetylsalicylic acid and gastrointestinal ulcers or bleeding--a cohort study of the effects of proton pump inhibitor use patterns

artículo científico publicado en 2013

Myeloperoxidase is not useful for the early assessment of patients with chest pain

artículo científico publicado en 2009

Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary artery disease

artículo científico publicado en 2004

Myocardial damage, inflammation and thrombin inhibition in unstable coronary artery disease

artículo científico publicado en 2003

Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial

artículo científico publicado en 2012

New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis

artículo científico publicado en 2013

Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study

artículo científico publicado en 2016

Pathophysiologic mechanisms of persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome

artículo científico publicado en 2008

Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation

artículo científico

Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial.

artículo científico publicado en 2014

Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial

artículo científico

Platelet inhibition assessed with VerifyNow, flow cytometry and PlateletMapping in patients undergoing heart surgery.

artículo científico publicado en 2009

Post-resuscitation myocardial dysfunction in out-of-hospital cardiac arrest patients randomized to immediate coronary angiography versus standard of care

scientific article published on 02 March 2020

RISK OF STROKE IN WOMEN AND MEN WITH ATRIAL FIBRILLATION AND ONLY ONE ADDITIONAL CHA2DS2-VASC RISK FACTOR

Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran

artículo científico publicado en 2009

Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial

artículo científico publicado en 2019

Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI

scientific article published on 01 August 2019

Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time

artículo científico publicado en 2017

Reply to Letters Regarding Article, “Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Tria

Response by Oldgren and Sundström to Letter Regarding Article, "Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study"

artículo científico publicado en 2018

Response to letter regarding article, "Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy".

artículo científico publicado en 2013

Response to letter regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial a

artículo científico publicado en 2014

Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”.

artículo científico publicado en 2013

Risk Markers of Incident Atrial Fibrillation in Patients with Coronary Heart Disease

scientific article published on 02 January 2021

Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial

artículo científico

Risk of ischemic stroke and utility of CHA2 DS2 -VASc score in women and men with atrial fibrillation

artículo científico publicado en 2019

Risk of mortality and stroke after atrial fibrillation - Authors' reply

artículo científico publicado en 2017

Risk prediction in chest pain patients by biochemical markers including estimates of renal function

artículo científico publicado en 2007

Risk prediction in patients with chest pain: early assessment by the combination of troponin I results and electrocardiographic findings

artículo científico publicado en 2005

Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial

artículo científico publicado en 2011

Safety and efficacy of double versus triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of NOAC-based randomized cli

artículo científico publicado en 2020

Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials.

artículo científico publicado en 2018

Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation

scientific article published on 09 December 2020

Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials

artículo científico publicado en 2020

Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial

artículo científico publicado en 2017

Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation.

artículo científico

Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease

scientific article published on 02 January 2021

Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis

scientific article published on 01 December 2019

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

article

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary

artículo científico publicado en 2018

The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation

artículo científico publicado en 2016

The ABC risk score for patients with atrial fibrillation - Authors' reply.

artículo científico publicado en 2016

The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study

artículo científico publicado en 2013

The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease

artículo científico publicado en 1999

The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.

artículo científico publicado en 2016

The platelet inhibiting effect of a clopidogrel bolus dose in patients on long-term acetylsalicylic acid treatment

artículo científico publicado en 2007

The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial

artículo científico publicado en 2008

The utility of coagulation activity for prediction of risk of mortality and cardiovascular events in guideline-treated myocardial infarction patients

artículo científico publicado en 2017

Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction ⬇️

artículo científico publicado el 23 de febrero de 2011

Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation

article

Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary

artículo científico publicado en 2016

Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial

artículo científico publicado en 2016

Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry.

artículo científico publicado en 2014

Wytyczne ESC dotyczące leczenia migotania przedsionków w 2016 roku, opracowane we współpracy z EACTS

Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals

artículo científico publicado en 2008

[The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary]

artículo científico publicado en 2018

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda